Steven Horwitz, MD
Dr. Horwitz is a medical oncologist at Memorial Sloan Kettering Cancer Center, New York, focusing on the care of patients with lymphoma, and with clinical expertise in all types of lymphomas. Dr. Horwitz’s research is aimed at developing an improved understanding of new therapies for patients with several less-common types of lymphoma, including T- cell lymphomas, cutaneous lymphomas, Hodgkin’s disease, and lymphomas in immunosuppressed patients after organ transplant (post-transplant lymphoproliferative disorders or PTLD).
Kathy D. Miller, MD
Dr. Miller received her MD in 1991 from the Johns Hopkins School of Medicine in Baltimore, MD. She completed internal medicine training at Hopkins then returned to her native Midwest for fellowship training at Indiana University, serving as Chief Fellow in 1997. She returned to Indiana University in 1999, attaining the rank of Professor and Ballvé-Lantero Scholar in 2014. Dr. Miller’s career has combined both laboratory and clinical research in breast cancer. She became chair of the ECOG-ACRIN Breast Core Committee in January 2014. In this role she works with academic scientists and community oncologists to develop trials that combine clinical and biologic endpoints yet remain feasible in non-academic settings. Dr. Miller honed her ability to coordinate multi-center trials as principal investigator for three previous ECOG trials. In addition she serves as principal investigator of the National Clinical Trials Network at Indiana University.
Eric Topol, MD
Dr. Topol is Director of the Scripps Translational Science Institute, Chief Academic Officer for Scripps Health, Professor of Translational Genomics at The Scripps Research Institute and a Senior Consultant cardiologist at Scripps Clinic. He chaired the Department of Cardiovascular Medicine at Cleveland Clinic for 15 years and in his last 5 years served as Chief Academic Officer and Provost of the Cleveland Clinic Lerner College of Medicine. He held a position as Professor at the University of Michigan for 6 years. His training included University of Rochester (medical school), University of California, San Francisco (internal medicine), Johns Hopkins (cardiology) and served as Program Director on an NIH $17.2 million grant–a Specialized Center of Clinically Oriented Research (SCCOR) evaluating molecular determinants of coronary artery disease. He has led a number of international large-scale randomized clinical trials (such as GUSTO) to advance therapies for myocardial infarction. Dr. Topol has been elected to the Institute of Medicine of the National Academy of Sciences, the American Association of Physicians, the American Society of Clinical Investigation, and the Johns Hopkins Society of Scholars. He has been recognized by the Institute of Scientific Information (ISI) to be in the top 10 cited biomedical researchers in medicine over the past decade.
Daniel D. Von Hoff, MD
Dr. Von Hoff is Physician in Chief and Director of Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is Chief Scientific Officer for US Oncology and for Scottsdale Healthcare’s Clinical Research Institute and he is also a Clinical Professor of Medicine, University of Arizona. Dr. Von Hoff graduated from Carroll College and received his medical degree from Columbia University College of Physicians and Surgeons. He went on to complete his internship and residency in internal medicine at the University of California, San Francisco, and a fellowship in medical oncology at the National Cancer Institute. Dr. Von Hoff became a professor in the departments of medicine and cellular and structural biology at the University of Texas Health Science Center, San Antonio. In 1989, he became the founding director of the Institute for Drug Development at the Cancer Therapy and Research Center in San Antonio and 10 years later he became the director of the cancer center and professor of medicine at the University of Arizona. He is currently serving a six-year term on the National Cancer Advisory Board and has served on the FDA’s Oncology Advisory Committee. Dr. Von Hoff is a past president of the American Association for Cancer Research, was on the AACR and the American Society of Clinical Oncology’s Board of Directors, and is a fellow of the American College of Physicians. He is the founder of Investigational New Drugs – The Journal of New Anticancer Agents and is currently editor-in-chief of Molecular Cancer Therapeutics. He was the associate editor for two AACR journals, Clinical Cancer Research and Cancer Research.
Kensei Tobinai, MD, PhD
Dr. Tobinai is Chief of Hematology Department at the National Cancer Center Hospital in Tokyo, Japan. Dr. Tobinai is an internationally regarded expert in medical oncology, in particular in lymphomas. His primary research interests focus on malignant lymphomas, including adult T-cell leukemia-lymphoma (ATL), molecular targeted therapy and antibody therapy. Dr. Tobinai has received many awards, including the Young Investigator award from the Japan Cancer Association, Best Doctors in Japan, award from Princess Takamatsu’s Cancer Research Fund as a visiting physician at Fred Hutchinson Cancer Research Center & Dana-Faber Cancer Institute, and a grant as a Visiting Scientist at Stanford University Medical Center, University of Nebraska Medical Center and Royal Marsden Hospital supported by the Research Grant of 10 Year Cancer Control Study, Ministry of Health, Labor and Welfare. He has been a member of several Japanese and International Hematology/Oncology societies, such as the Japanese Cancer Association, the Japanese Society of Hematology, the Japanese Society of Lymphoreticular Tissue Research (President), the Japanese Society of Medical Oncology, the Japanese Society of Cancer Therapy, and the Japan Society for Hematopoietic Cell Transplantation. He has been named Chair of Japan Clinical Oncology Group (JCOG) in 2014. Dr. Tobinai is a member of several prestigious societies such as ASCO and ASH, and he has contributed to the organization of several international conferences. He has published over 250 articles and he serves as Associate Editor of the Japanese Journal of Clinical Oncology and as an Editorial Board Member or reviewers of numerous international journals.
Kunihiro Tsukasaki, MD, PhD
Dr. Tsukasaki received his M.D. and Ph.D. degrees from Nagasaki University in1984 and 1997 respectively. He served as resident in the Department of Hematology at Nagasaki University Hospital until 1989 and then as staff physician in the Department of Internal Medicine, Isahaya General Hospital until 1991. Dr. Tsukasaki was chief resident in the Department of Hematology, Nagasaki University Hospital from 1991 until 1994, where after he served as Staff Physician at Shimabara Prefectural Hospital until 1996. From 1996 to 1998 Dr. Tsukasaki held the post of Instructor in the Department of Hematology at Nagasaki University Hospital and from 1998 to 2000 was a Visiting Scientist in the Department of Medicine, Division of Hematology/Oncology, Cedars-Sinai Medical Center in the US. He then returned to Nagasaki University Hospital where he served as Instructor and Lecturer in the Department of Hematology until 2004 when he was appointed as Associate Professor, Department of Hematology, Atomic Bomb Disease Institute Nagasaki University Graduate School of Biomedical Science, a post that he held until becoming Chief of the Department of Hematology, National Cancer Center Hospital East in 2012. Dr. Tsukasaki is a member of numerous Japanese and International Hematology/Oncology societies and serves on a variety of advisory committees including as Chairman of the Lymphoma Study Group of JCOG. He is a member of the Editorial board of the “Japanese Journal of Clinical Oncology” as well as “Advances in Hematology” and Associate Editor of “Annals of Oncology”. Dr. Tsukasaki is a reviewer for multiple scientific publications and is a prolific author of peer-reviewed publications.
Toshiki Watanabe, MD, PhD
Dr. Toshiki Watanabe received his M.D. and Ph.D. degrees from the Faculty of Medicine, The University of Tokyo in 1979 and 1987, respectively. In 1982, he was a Visiting Researcher, Department of Viral Oncology, Cancer Institute, Japanese Foundation for Cancer Research. In 1985 he served as Research associate, Staff Physician, 4th Department of Internal Medicine, Faculty of Medicine, The University of Tokyo. In 1987, he was a Visiting Researcher, Department of Immunology, Scripps Institute, La Jolla, CA and in 1988 he was a Research Fellow, Department of Viral Oncology, Cancer Institute, Japanese Foundation for Cancer Research. In 1990 he became Associate Professor, The Institute of Medical Sciences, The University of Tokyo and in 2004 Professor, Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo. In 2007, he was appointed Chairman, Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo. Dr. Watanabe is a Member of the Japanese Hematology Association, the Japanese Cancer Association and the American Society of Hematology. He also serves as a Board member of the International Retrovirology Association (President in 2007), International Association for Comparative Research of Leukemia and Related Diseases (IACRLRD) (President 2009-2011) and President of the Japanese Association of HTLV-1 and associated Diseases (JAHAD). Dr. Watanabe is the recipient of several awards, including the 2007 International Retrovirology Association (IRA), David McFarlin Award and the 2008 13th The Prince Hitachi Prize for Comparative Oncology. He has published more than 150 original papers.
Won Seog Kim, MD, PhD
Dr. Won-Seog Kim is a Professor of Division of Hematology-Oncology at Samsung Medical Center and in charge of malignant lymphoma service. He is working as the key member for lymphoma working party of Korean Society of Hematology and consortium for improved survival of lymphoma (CISL). He is current chairman of Korean Society of Hematology lymphoma working party. He is also one of the founding members of Asian Lymphoma study group (ALSG). Malignant lymphoma is Dr Kim’s area of special interest. Recently, he is much more focused on the management of T or NK/T-cell lymphomas and new compounds. He has published more than 210 peer-reviewed articles on clinical research in malignant lymphoma. He has served on the editorial board of American Journal of Blood Research (AJBR) and faculty of F1000. His award achievements include Outstand Research Award from Korean Society of Hematology (2010) and Best Achievement in inpatient care (2006) and in Research (2007) from Samsung Medical Center.